We read with interest 'Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma'. 1 Dimopoulos et al. reported a retrospective post-hoc pooled analysis by using the data from two randomized trials, MM-009 and MM-010, which showed improved outcomes in patients with relapsed/refractory multiple myeloma treated with lenalidomide and dexamethasone. An important finding in Dimopoulos's report is the association between humoral improvement (uninvolved immunoglobulin A) and the long-term benefit of therapy. It shows humoral responders had better progression-free survival and overall survival compared with humoral nonresponders, in Figure 2 . However, humoral response could occur at anytime from cycle one to ten. If the data was analyzed by using a log-rank test or time-independent Cox regression model, it is likely that an 'immortal time bias' could interfere with this result. [2] [3] [4] [5] 'Immortal time' refers to a time interval during the follow-up period in which the outcome could never occur because of exposure definition. For example, death cannot occur in the first 5 months of follow-up, in patients who had humoral response after at least six cycles (of each 28-day cycle). In conventional survival analysis, the immortal time bias can confer a spurious survival advantage to the responder group if the response is measured in the middle of the follow-up period but not at the beginning of the trial. Humoral improvement might predict the outcomes of the patients with multiple myeloma. Nevertheless, the result should be analyzed using time-dependent analysis, 2,5 such as Cox regression with response status as a time-dependent covariate. We look forward to see such reanalysis of the original data. 
